Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Publication date: Available online 21 September 2020Source: The Lancet HaematologyAuthor(s): Steven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, Victoria Cacheux, Violaine Safar, Barbara Burroni, Stéphanie Guidez, Thomas Gastinne, Danielle Canioni, Catherine Thieblemont, Hervé Maisonneuve, Caroline Bodet-Milin, Roch Houot, Lucie Oberic, Krimo Bouabdallah, Charles Bescond, Ghandi Damaj, Arnaud Jaccard, Nicolas Daguindau, Anne Moreau
Source: The Lancet Haematology - Category: Hematology Source Type: research